About Tizig

Tizig Pharma Pvt. Ltd. (TIZIG) proudly leads Nepal’s first and only one-pharmaceutical company, producing high-quality tablet and capsule dosage forms for cancer treatment. We established TIZIG in 2018 and launched our products on February 15, 2022, after securing all necessary approvals from the Department of Drug Administration (DDA), Ministry of Health and Population, Nepal.

We tackle the challenges of unavailability and irregularities in anticancer medicines in Nepal by producing high-quality, accessible, and affordable oncology medications. Operating from our state-of-the-art manufacturing facility, we ensure every product meets the highest quality and efficacy standards, addressing the needs of cancer patients and oncologists.

We uphold global manufacturing standards through our partnership with S P Accrue Lab Pvt. Ltd., Hyderabad, India (an EU GMP-certified facility). Our collaboration, approved by Nepal’s Department of Industry and DDA, ensures our products adhere to pharmacopeial guidelines like USP, BP, EP, and WHO norms.

We focus on producing cytotoxic, biological, and protein kinase inhibitor molecules to close the gaps in cancer treatment options. We rigorously test our medicines for quality and efficacy, ensuring compliance with international benchmarks. While serving patients across Nepal, we also expand our reach globally, supplying medication to countries such as India, Ukraine, Australia, and Armenia, with the approval of their respective drug regulatory authorities.

At TIZIG, we commit to excellence by prioritizing quality, safety, and continuous improvement. Our mission drives us to deliver affordable and effective cancer treatment solutions, ensure patient satisfaction, and make a global impact.